Lamotrigine

Indications

• FDA-approved for maintenance treatment of bipolar I disorder in adults to delay the time to recurrence of mood episodes.
• FDA-approved as adjunctive therapy for partial-onset seizures, generalized tonic-clonic seizures, and Lennox-Gastaut syndrome from age 2.
• FDA-approved for conversion to monotherapy in patients aged 16 and older with partial-onset seizures taking a single enzyme-inducing anticonvulsant.
• Off-label acute treatment of bipolar depression, where meta-analysis shows a small but real benefit that grows in more severe depression.
• Off-label augmentation in treatment-resistant unipolar depression and for affective instability in borderline personality disorder.
• It has no antimanic efficacy, so patients with prominent manic recurrence need a different or additional agent.

Mechanism of action

• Blocks voltage-gated sodium channels in the inactivated state, stabilizing neuronal membranes and reducing repetitive high-frequency firing.
• Inhibits presynaptic glutamate and aspartate release, an effect proposed to underlie the antidepressant and antikindling actions.
• Modulates high-voltage-activated calcium channels, further reducing excitatory transmission without direct GABA receptor effects.
• Absence of significant histamine, muscarinic, or adrenergic blockade explains the weight neutrality and minimal sedation.
• The gradual onset over weeks reflects both the mandated slow titration and downstream changes in glutamatergic signaling.

Pharmacokinetics

• Oral bioavailability is essentially complete and unaffected by food, with peak plasma concentrations at 1 to 5 hours.
• Metabolism is by UGT1A4 glucuronidation with renal excretion of the conjugate; there are no clinically important CYP interactions.
• The half-life is 25 to 33 hours on monotherapy, roughly 59 hours when valproate inhibits glucuronidation, and about 13 hours with inducers.
• Estrogen-containing contraceptives induce glucuronidation and cut lamotrigine levels by about half, with rebound during the pill-free week.
• Clearance rises up to two- to threefold during pregnancy and returns to baseline within weeks postpartum, requiring planned dose changes.

Dosing

• Standard monotherapy titration is 25 mg/day for weeks 1-2, 50 mg/day for weeks 3-4, 100 mg at week 5, and 200 mg/day at week 6.
• With valproate, halve everything: 25 mg every other day for weeks 1-2, 25 mg/day weeks 3-4, 50 mg week 5, then 100 mg/day target.
• With an enzyme inducer and no valproate, double it: 50 mg/day weeks 1-2, 100 mg/day weeks 3-4, then increase to a target of 400 mg/day.
• Never exceed these steps; escalating faster or starting higher is the single most avoidable cause of serious rash.
• If therapy lapses for more than 5 half-lives, roughly 5 days, restart the entire titration from the beginning rather than resuming the prior dose.
• Reduce the maintenance dose in significant renal impairment and by 25 to 75 percent in moderate to severe hepatic impairment.

Adverse effects

• Benign maculopapular rash occurs in about 10 percent, typically in weeks 2 to 8, and cannot be reliably distinguished early from serious rash.
• Serious rash requiring hospitalization occurs in roughly 0.08 to 0.3 percent of adults and 0.3 to 0.8 percent of children aged 2 to 16.
• Headache, dizziness, nausea, diplopia, ataxia, and insomnia are common and generally dose-related during titration.
• It is weight neutral and largely free of sexual dysfunction, which is a major reason for its acceptability in maintenance therapy.
• Rare serious events include aseptic meningitis, hemophagocytic lymphohistiocytosis, blood dyscrasias, and multiorgan hypersensitivity.
• In vitro class IB sodium channel blockade underlies an arrhythmia warning for patients with structural or ischemic heart disease.

Monitoring

• Counsel at every titration visit to stop the drug and call immediately for any rash, especially with fever, mucosal lesions, or facial swelling.
• No routine serum levels or laboratory monitoring is required for mood indications in otherwise healthy adults.
• Check levels when clearance changes are expected, notably during pregnancy, postpartum, or when a contraceptive is started or stopped.
• Consider an ECG before starting in patients with known structural heart disease, conduction disease, or clinically significant ischemia.
• Monitor for persistent fever, rash, hepatosplenomegaly, and cytopenias, which suggest hemophagocytic lymphohistiocytosis and require urgent workup.

Interactions

• Valproate inhibits glucuronidation and roughly doubles lamotrigine levels, so the starting dose and target must be halved.
• Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin induce glucuronidation and roughly halve lamotrigine concentrations.
• Combined oral contraceptives lower levels by about 50 percent; stopping the pill without lowering the lamotrigine dose can cause toxicity.
• Lamotrigine modestly raises carbamazepine epoxide concentrations in some patients, producing diplopia and dizziness at unchanged doses.
• Avoid rapid dose escalation with any interacting drug, and treat every dose change in an interacting agent as a reason to reassess.

Special populations

• Lamotrigine has among the most reassuring pregnancy registry data of the anticonvulsants, without a clear malformation signal at usual doses.
• Clearance can triple by the third trimester, so check levels each trimester and plan a rapid postpartum taper toward the preconception dose.
• Relative infant dose in breast milk is comparatively high; monitor the nursing infant for rash, sedation, and poor feeding.
• Pediatric patients aged 2 to 16 have several times the adult risk of serious rash, so titration discipline matters even more.
• Older adults tolerate lamotrigine well overall, but reduce doses when renal or hepatic function is impaired.

Clinical pearls

• Miss 5 days of doses and you must restart the full titration; do not resume at the old dose.
• Adding valproate halves the lamotrigine dose; adding carbamazepine roughly doubles it.
• Any rash in the first 8 weeks means stop the drug now and evaluate, not watch and wait.